NEWSROOM | Galderma

Galderma receives Positive Opinion through European Decentralised Procedure for Approval of EPIDUO® 0.3% / 2.5% gel for Acne Patient

Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biotherapy for Skin Diseases

FDA Approves Galderma’s prescription-strength Differin Gel for over-the-counter use in treatment of acne in the U.S.

Galderma’s Epiduo Gel approved for the treatment of acne in Japan

Galderma Trifarotene Development Program Meets Key Milestone for Lamellar Ichthyosis Orphan Disease

Nestlé Skin Health SHIELD Receives Corporate Leadership Award from the American Skin Association

Nestlé Skin Health to Form Non-Prescription Acne Joint Venture with Guthy-Renker

ATP and Nestlé Skin Health’s Daylong Announce Exclusive Global Sun Care Partnership

Nestlé Skin Health Appoints Dr. Johannes J. Baensch as Chief Scientific Officer

Nestlé Skin Health Invests $46 Million in Factory Extension in Canada

Nestlé Skin Health Promotes a Life Course of Healthy Skin and Provides New Educational Tools During Active Aging Week 2015

Nestlé Skin Health builds CHF 54 million factory in Brazil